Yuen Tsang
Overview
Explore the profile of Yuen Tsang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burger C, Tang W, Tsang Y, Panjabi S
JAMA Netw Open
. 2024 Sep;
7(9):e2434691.
PMID: 39312239
Importance: A subgroup analysis of a randomized clinical trial established the efficacy of selexipag plus background therapy (monotherapy or double oral therapy [DOT]) vs placebo plus background therapy and found...
2.
Burger C, Tang W, Tsang Y, Panjabi S
Pulm Circ
. 2024 Aug;
14(3):e12415.
PMID: 39157055
Selexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily...
3.
Burger C, Tsang Y, Chivers M, Vekaria R, Doad G, Atkins N, et al.
Clinicoecon Outcomes Res
. 2024 Jun;
16:447-459.
PMID: 38831921
Purpose: Pulmonary arterial hypertension (PAH) is a rare and progressive pulmonary vascular disease that can result in right heart failure and death. Oral prostacyclins play an important role in the...
4.
Tsang Y, Stokes M, Kim Y, Tilney R, Panjabi S
Clin Respir J
. 2023 Oct;
17(12):1209-1222.
PMID: 37804160
Background: Oral selexipag, a prostacyclin pathway agent (PPA), is effective in patients with pulmonary arterial hypertension (PAH). The objective of this study is to assess the impact of initiating oral...
5.
McConnell J, Bilir S, Xu Y, Tsang Y, Panjabi S
J Med Econ
. 2023 Oct;
26(1):1349-1355.
PMID: 37800591
Aims: Pulmonary arterial hypertension (PAH) is a rare, progressive, and ultimately fatal form of the broader condition pulmonary hypertension. ESC/ERS guidelines recommend therapy targeting the prostacyclin pathway for patients not...
6.
Sargent T, Tsang Y, Panjabi S, Funtanilla V, Germack H, Gauthier-Loiselle M, et al.
Adv Ther
. 2023 Sep;
40(11):5037-5054.
PMID: 37728697
Introduction: Connective tissue disorders (CTDs) are the most frequent diseases associated with pulmonary arterial hypertension (PAH). Despite advances in treatment, the prognosis of CTD-related PAH remains poor. To help identify...
7.
Farber H, Chakinala M, Cho M, Frantz R, Frick A, Lancaster L, et al.
Pulm Circ
. 2023 Jul;
13(3):e12258.
PMID: 37427090
Pulmonary arterial hypertension (PAH) is a rare, life-limiting disease. PAH registries provide real-world data that complement clinical trial data and inform treatment decisions. The TRIO comprehensive, integrated patient data repository...
8.
Papademetriou E, Liu X, Beaudet A, Tsang Y, Potluri R, Panjabi S
J Med Econ
. 2023 Apr;
26(1):644-655.
PMID: 37086091
Background: Pulmonary arterial hypertension (PAH), a rare vasculopathy progressively leading to right heart failure and death, is associated with considerable economic burden. Oral prostacyclin pathway agents (PPAs) like selexipag and...
9.
Tsang Y, Panjabi S, Funtanilla V, Germack H, Gauthier-Loiselle M, Manceur A, et al.
Pulm Circ
. 2023 Apr;
13(2):e12218.
PMID: 37051491
Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue disorders (CTDs). This study provides a contemporary assessment of the economic burden of CTD + PAH and PAH in the...
10.
Zhang C, Tsang Y, He J, Panjabi S
Adv Ther
. 2023 Apr;
40(5):2481-2492.
PMID: 37024760
Introduction: US claims-based analyses emphasize the substantial hospitalization burden of patients with pulmonary arterial hypertension (PAH) and the significant need for improved monitoring and more timely interventions. A claims-based predictive...